Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Total Non-Current Liabilities (2016 - 2025)

Historic Total Non-Current Liabilities for Adma Biologics (ADMA) over the last 14 years, with Q3 2025 value amounting to $137.4 million.

  • Adma Biologics' Total Non-Current Liabilities fell 1322.49% to $137.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $137.4 million, marking a year-over-year decrease of 1322.49%. This contributed to the annual value of $139.3 million for FY2024, which is 2803.15% down from last year.
  • Latest data reveals that Adma Biologics reported Total Non-Current Liabilities of $137.4 million as of Q3 2025, which was down 1322.49% from $160.1 million recorded in Q2 2025.
  • Adma Biologics' 5-year Total Non-Current Liabilities high stood at $199.8 million for Q3 2022, and its period low was $120.4 million during Q2 2021.
  • Its 5-year average for Total Non-Current Liabilities is $166.8 million, with a median of $180.7 million in 2022.
  • As far as peak fluctuations go, Adma Biologics' Total Non-Current Liabilities surged by 5125.53% in 2022, and later crashed by 3029.82% in 2025.
  • Quarter analysis of 5 years shows Adma Biologics' Total Non-Current Liabilities stood at $134.7 million in 2021, then skyrocketed by 45.63% to $196.1 million in 2022, then decreased by 1.32% to $193.6 million in 2023, then dropped by 28.03% to $139.3 million in 2024, then decreased by 1.36% to $137.4 million in 2025.
  • Its Total Non-Current Liabilities was $137.4 million in Q3 2025, compared to $160.1 million in Q2 2025 and $137.1 million in Q1 2025.